Navigation Links
TNF Treatment for Rheumatoid Arthritis Boosts Skin Cancer Risk
Date:9/7/2011

WEDNESDAY, Sept. 7 (HealthDay News) -- Treating rheumatoid arthritis (RA) patients with tumor necrosis factor (TNF) inhibitors appears to increase their risk of developing skin cancer, a new review of prior research indicates.

However, TNF inhibitors, which include infliximab (Remicade), adalimunab (Humira), and etanercept (Enbrel), do not appear to boost the risk for developing other forms of cancer, the researchers added.

The findings stem from an analysis of 21 previous studies conducted between 1998 and 2010, as well as eight study summaries that had been presented at research conferences during the same timeframe. All the studies had focused on the potential for cancer risk in association with the use of standard TNF inhibitors.

"This systematic review and meta analysis provides reassurance to physicians and patients that the treatment of [rheumatoid arthritis] with TNF inhibitors does not increase the risk of malignancy, particularly lymphoma," the French study team said in a news release from Annals of the Rheumatic Diseases, which published the report in its current online issue.

"However, it does appear to increase the risk of skin cancer, including melanoma," added the French team, led by Prof. Xavier Mariette from Paris-Sud University's rheumatology service in Ile de France.

The authors noted that RA has previously been shown to increase the risk for developing certain types of cancer, including both lung cancer and lymphoma, while decreasing the risk for other cancers, including bowel and breast.

However, the question of TNF inhibitor treatments as a cancer risk has remained a subject of debate.

All told, the current review looked at a collection of studies involving more than 40,000 patients who had been exposed to nearly 150,000 years of TNF inhibitor drugs.

Seven of the studies indicated no notable risk increase for any type of cancer associated with the use of TNF meds. Another two long-term studies similarly suggested that while RA patients who had previously had cancer faced a higher likelihood for a second bout, TNF treatments alone posed no additional cancer risk.

But four other studies collectively demonstrated that TNF inhibitors boosted the risk for non-melanoma skin cancer by 45 percent. And another two studies suggested that the RA treatment raised the specific risk for developing melanoma by nearly 80 percent.

Dr. W. Hayes Wilson, chief of rheumatology at Piedmont Hospital in Atlanta, said the findings should help guide physicians on potential RA treatment complications.

"I don't think this is particularly surprising, given that there's long been a concern about cancer risk in the back of our minds," he noted. "And, in fac,t this is somewhat reassuring on the front of solid cancers that there's nothing to be alarmed about."

"But while we can perhaps now put aside our worries about other types of cancers, this does give us some indication that we need to be vigilant when it comes to skin cancer," Wilson added. "And we certainly need to have a high index of suspicion if a patient has a skin abnormality, and make certain that they see their dermatologist."

More information

For more on rheumatoid arthritis, visit the National Institutes of Arthritis and Musculoskeletal and Skin Diseases.

--Alan Mozes

SOURCES: Annals of the Rheumatic Diseases, Sept. 7, 2011, news release; W. Hayes Wilson, M.D., chief of rheumatology, Piedmont Hospital, Atlanta


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Plants could pave the way for new ovarian cancer treatments
2. Incisionless surgery now available as an investigational treatment for esophageal disorder
3. Thyroid cancer treatment varies by hospital, U-M study finds
4. Childhood maltreatment linked to long-term depression risk and poor response to treatment
5. Lawson scientist presents joint pain treatment 2.0
6. New treatment option for advanced prostate cancer
7. Sleep Apnea Makes Quick Return When Treatment Stops
8. Study of Bone Cancer in Dogs May Improve Treatment in Kids
9. Traumatic brain injury: NIH-funded researchers will assess biomarkers for diagnosis and treatment
10. Barrier to effective treatment for seniors -- the cost of medicine
11. Caution Urged in Intensive Treatment of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
TNF Treatment for Rheumatoid Arthritis Boosts Skin Cancer Risk
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: